**Core Concept**
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a genetic disorder affecting the enzyme responsible for maintaining the integrity of red blood cells. Individuals with this deficiency are susceptible to hemolysis (red blood cell destruction) when exposed to certain medications or substances. Understanding the pharmacological properties of various drugs is crucial in managing patients with G6PD deficiency.

**Why the Correct Answer is Right**
Corticosteroids, such as prednisone and methylprednisolone, do not cause hemolysis in G6PD deficiency. This is because corticosteroids do not generate reactive oxygen species that can oxidize hemoglobin and lead to hemolysis. In contrast, drugs like primaquine and dapsone are known to induce oxidative stress, triggering hemolysis in individuals with G6PD deficiency.

**Why Each Wrong Option is Incorrect**
**Option A:** Primaquine is a well-known cause of hemolysis in G6PD deficiency, as it generates reactive oxygen species that can oxidize hemoglobin, leading to red blood cell destruction.
**Option B:** Dapsone is another medication that can cause hemolysis in G6PD deficiency, as it induces oxidative stress and generates reactive oxygen species.
**Option D:** Methylene blue is a compound that can also cause hemolysis in G6PD deficiency, as it generates superoxide anions that can oxidize hemoglobin.

**Clinical Pearl / High-Yield Fact**
When managing patients with G6PD deficiency, it is essential to avoid medications that can induce oxidative stress, such as primaquine, dapsone, and methylene blue. Corticosteroids, on the other hand, are generally safe and can be used as a treatment option in these patients.

**✓ Correct Answer: C. Corticosteroids**